CRF2 receptor agonists and their use in therapy
Patent Information
- Application Number
- DE602023010093
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-02-23
- Filing Date
- 2023-02-21
- Publication Date
- 2025-12-24
- Estimated Expiration
- 2043-02-21
AI Technical Summary
The extremely short half-life of urocortins limits their therapeutic use, necessitating continuous intravenous infusion, which is impractical for chronic conditions like heart failure and diabetes, and there is a need for CRF2 receptor agonists with improved pharmacokinetic properties for long-term treatment.
Development of peptide analogues of UCN2 with specific modifications, such as N-terminal acetylation or methylation, and alterations at position 32, to enhance stability and solubility, allowing for once-daily subcutaneous administration.
The modified peptides exhibit improved stability and solubility, enabling effective CRF2 receptor agonism for the treatment of cardiovascular diseases, obesity, diabetes, sarcopenia, cachexia, and pulmonary hypertension, reducing the need for continuous infusion.